港股异动丨来凯医药一度飙升超30%，LAE102针对治疗肥胖症I期MAD研究取得积极初步结果

Core Viewpoint - The stock price of Lai Kai Pharmaceutical-B (2105.HK) surged by 31.72% to HKD 19.6, reaching a new high since August 15, following the announcement of positive preliminary results from the Phase I multi-dose escalation study (MAD study) of LAE102 for obesity treatment in China [1] Group 1: Study Results - The MAD study showed encouraging trends in muscle gain and fat loss [1] - In the 5th week, participants in the LAE102 6mg/kg dosage group had an average lean body mass increase of 1.7% compared to baseline, while average fat mass decreased by 2.2% [1] - After adjusting for the placebo group, the average lean body mass increase reached 4.6%, and average fat mass decreased by 3.6% [1]